Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase 2 Completed
60 enrolled 8 charts
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Phase 1/2 Completed
43 enrolled 18 charts
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Phase 1 Completed
16 enrolled
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1/2 Completed
110 enrolled 17 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 1/2 Completed
52 enrolled 10 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
48 enrolled
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Phase 1 Completed
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Completed
105 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Phase 2 Completed
48 enrolled 5 charts
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
89 enrolled 9 charts
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Phase 1 Completed
42 enrolled
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
Phase 3 Completed
230 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
18 enrolled
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma
Phase 3 Completed
400 enrolled
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
Phase 2 Completed
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Phase 2 Completed
35 enrolled
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Phase 1 Completed
37 enrolled
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Phase 1/2 Completed
58 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
27 enrolled
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase 1 Completed
69 enrolled
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Phase 1 Completed
60 enrolled
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
FR901228 in Treating Patients With Hematologic Cancer
Phase 1 Completed
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Phase 1/2 Completed
28 enrolled
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Phase 1 Completed
60 enrolled
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
72 enrolled
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
36 enrolled